Document Detail


Umbilical cord levels of sclerostin, placental weight, and birth weight are predictors of total bone mineral content in neonates.
MedLine Citation:
PMID:  23221033     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: During pregnancy, changes occur in the maternal calcium homeostasis to fulfill fetal demand. We hypothesized that the fibroblast growth factor 23 (FGF23) system and Wnt signaling pathway are important for normal skeletal development in the offspring.
AIMS: Circulating α-klotho, FGF23, sclerostin, and 25-hydroxyvitamin D (25(OH)D) at the fetal and maternal sides of the placenta were measured to investigate associations with newborn bone mass independent of maternal BMI, calcium and phosphate levels, placental weight, and birth weight.
METHODS: In a prospective cohort of healthy pregnant women, the total body bone mineral content (BMC) in 202 newborns was measured by dual-energy X-ray absorptiometry. Maternal circulating levels of the biomarkers were measured at gestational weeks 30-32 and in umbilical cord plasma (UCP) at birth.
RESULTS: Mean α-klotho and sclerostin concentrations in the UCP were significantly higher than maternal levels (3004 vs 1077  pg/ml; P<0.001 and 629 vs 346  pg/ml; P<0.001 respectively), and mean 25(OH)D was lower (31 vs 45  nmol/l; P<0.001). The UCP and maternal FGF23 levels were similar. No significant effects of maternal biomarkers on BMC were found in regression analyses. Among UCP biomarkers, only UCP sclerostin was significantly associated with BMC in univariate analyses, and the effect remained significant after adjustment for birth weight and other confounders.
CONCLUSIONS: We found that UCP sclerostin levels, birth weight, and placental weight were significant predictors of neonatal BMC but found no evidence for a main role of maternal levels of α-klotho, FGF23, sclerostin, or 25(OH)D nor of UCP levels of α-klotho, FGF23, or 25(OH)D.
Authors:
Kristin Godang; Kathrine Frey Frøslie; Tore Henriksen; Gunhild A Isaksen; Nanna Voldner; Tove Lekva; Thor Ueland; Jens Bollerslev
Related Documents :
23105353 - Unusual changes in colostrum composition in lactating indian women having medical compl...
23009963 - When is primary cesarean appropriate: maternal and obstetrical indications.
1163583 - The effect of prostaglandin f2alpha on the placental progesterone level in midtrimester...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-02-15
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  168     ISSN:  1479-683X     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-18     Completed Date:  2013-04-08     Revised Date:  2013-05-08    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  371-8     Citation Subset:  IM    
Affiliation:
Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital Rikshospitalet, PO Box 4950 Nydalen, Oslo 0424, Norway. kgodang@ous-hf.no
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorptiometry, Photon
Biological Markers / blood
Birth Weight*
Bone Density
Bone Development*
Bone Morphogenetic Proteins / blood*
Bone and Bones / metabolism
Cohort Studies
Female
Fetal Blood
Fetal Development*
Genetic Markers
Glucuronidase / blood
Humans
Infant, Newborn
Male
Organ Size
Placenta / growth & development*
Pregnancy
Pregnancy Trimester, Third / blood
Prospective Studies
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Bone Morphogenetic Proteins; 0/Genetic Markers; 0/SOST protein, human; EC 3.2.1.31/Glucuronidase; EC 3.2.1.31/klotho protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Red cell distribution width is an independent predictor of mortality in hip fracture.
Next Document:  Routine screening for Cushing's syndrome is not required in patients presenting with hirsutism.